Trial Profile

Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination with Paclitaxel in Subjects with R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Sep 2024 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Pathology outcomes from the NIVOTAX trial, results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
08 Nov 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com